|
Orthologous residues
|
|
eEF‑2 (human): T57‑p, eEF‑2 (mouse): T57‑p, eEF‑2 (rat): T57‑p, eEF‑2 (rabbit): T56‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Disease tissue studied:
major depressive disorder
|
|
Relevant cell lines - cell types - tissues:
'brain, hippocampus', neuron-'brain, hippocampus'
|
|
Cellular systems studied:
primary cultured cells, tissue
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
2-amino-5-phosphonopentanoic acid
|
|
|
|
decrease
|
|
|
ketamine
|
|
|
|
decrease
|
|
|
TTX
|
|
|
|
no change compared to control
|
|
|
TTX
|
2-amino-5-phosphonopentanoic acid
|
|
|
no effect upon treatment-induced decrease
|
|
|
TTX
|
ketamine
|
|
|
no effect upon treatment-induced decrease
|
|
|
rottlerin
|
|
|
|
decrease
|
|
|
1-hexadecyl-2-methyl-3- (phenylmethyl)-1H-imidazolium iodide
|
|
|
|
decrease
|
|
|
